Philippinen - Englisch - FDA (Food And Drug Administration)

virbac philippines inc.; distributor: virbac philippines inc. - inactivated bordetella bronchiseptica , pasteurella multocida , actinobacillus pleuropneumoniae , mycoplasma hyopneumoniae , streptococcus suis , haemophilus parasuis vaccine (vet.) - suspension for injection (im) - formulation: each 1 ml (dose) contains: bordetella bronchiseptica -1 od bordetella bronchiseptica (dnt)-200 ug/ml pasteurella multocida (type a and d)-i od p. multocida type a (omp)-30 ug/ml actinobacillus pleuropneumoniae (serotype 2 and 5)-1 od p. multocida type d (dnt)-200 ug/ml mycoplasma hvopneumoniae-0.12 od a. pleuropneumoniae serotype 2 and 5 (toxin) 10 ug/ml streptococcus suis (type 2)-0.45 od haemophilus parasuis (serotype 1, 4 and 5)-0.45 od od - optical density at 410 nm absorbance (elisa) dnt – dermonecrotic toxin omp - outer membrane protein

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

deseret biologicals, inc. - adenosine triphosphate disodium (unii: 5l51b4dr1g) (adenosine triphosphate - unii:8l70q75fxe), cinnamic acid (unii: u14a832j8d) (cinnamic acid - unii:u14a832j8d), escherichia coli (unii: 514b9k0l10) (escherichia coli - unii:514b9k0l10), herring sperm dna (unii: 51fi676n6f) (herring sperm dna - unii:51fi676n6f), shigella dysenteriae (unii: 1ep6r5562j) (shigella dysenteriae - unii:1ep6r5562j), echinacea angustifolia whole (unii: vb06av5us8) (echinacea angustifolia - unii:vb06av5us8), enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), helicobacter pylori (unii: u09w5jol3z) (helicobacter pylori - unii:u09w5jol3z), helicobacter pylori dna (unii: 14zy3jp7m6) (helicobacter pylori dna - unii:14zy3jp7m6), legionella pneumophila (unii: tjr6zfy0f0) (legionella pneumophila - unii:tjr6zfy0f0), listeria monocytogenes (unii: 3o44k14a86) (listeria monocytogenes - unii:3o44k14a86), malic acid (unii: 817l1n4ckp) (malic acid - unii:817l1n4ckp), mycoplasma pneumoniae (unii: jqe470fad0) (mycoplasma pneumoniae - unii:jqe470fad0), sodium diethyl oxalacetate (unii: 6ca025y4fg) (diethyl oxalacetate - unii:15s56468g7), orotic acid monohydrate (unii: 91532s02ao) (orotic acid - unii:61h4t033e5), petroselinum crispum whole (unii: 1wza4y92ex) (petroselinum crispum - unii:1wza4y92ex), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), proteus mirabilis (unii: c177vr41dv) (proteus mirabilis - unii:c177vr41dv), proteus morganii (unii: 56x6lid5zy) (proteus morganii - unii:56x6lid5zy), proteus vulgaris (unii: 11t9hco30o) (proteus vulgaris - unii:11t9hco30o), pseudomonas aeruginosa (unii: y793w5v55n) (pseudomonas aeruginosa - unii:y793w5v55n), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), salmonella enterica enterica serovar typhi (unii: 760t5r8b3o) (salmonella enterica enterica serovar typhi - unii:760t5r8b3o), shigella sonnei (unii: oo358e3009) (shigella sonnei - unii:oo358e3009), streptococcus agalactiae (unii: 2b3763s671) (streptococcus agalactiae - unii:2b3763s671), streptococcus equinus (unii: r2p4nkp3zk) (streptococcus equinus - unii:r2p4nkp3zk), streptococcus dysgalactiae (unii: ln0sh02y5m) (streptococcus dysgalactiae - unii:ln0sh02y5m), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j33mjj1), streptococcus uberis (unii: o84v4zk4bx) (streptococcus uberis - unii:o84v4zk4bx), streptococcus viridans group (unii: nnv2379hkr) (streptococcus viridans group - unii:nnv2379hkr) - adenosinum triphosphoricum dinatrum – mucus congestion, cinnamic acid – bladder discomfort, colibacillinum cum natrum muriaticum – stomach discomfort, dna joint discomfort, dysentery bacillus - fever, echinacea (angustifolia) - headache, enterococcus faecalis – mucus congestion, helicobacter pylori – stomach discomfort, helicobacter pylori dna – stomach discomfort, legionella pneumophila - cough, listeria monocytogenes – occasional diarrhea, malicum acidum – joint discomfort, mycoplasma pneumoniae – mucus congestion, natrum oxalaceticum – bladder discomfort, oroticum acidum – stomach discomfort, petroselinum sativum – fever, pneumococcinum - headache, proteus (mirabilis) – mucus congestion, proteus (morgani) – stomach discomfort, proteus (vulgaris) – bladder discomfort, pseudomonas aeruginosa – fever, riboflavinum – headache, salmonella typhi nosode – stomach discomfort, shigella sonnei – occasional diarrhea, streptococcus agalactiae - couch, streptococcus bovis – joint discomfort, streptococcus dysgalactiae – joint discomfort, streptococcus mutans - fever, streptococcus uberis – fever, streptococcus viridans – fever • for the temporary relief of symptoms including: • mucus congestion • stomach discomfort • fever • headache • cough • joint discomfort • occasional diarrhea • bladder discomfort these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Philippinen - Englisch - FDA (Food And Drug Administration)

virbac philippines inc.; distributor: virbac philippines inc. - inactivated streptococcus agalactiae fish vaccine (vet.) - emulsion for injection (ip) - formulation: each 0.1 ml (dose) contains: streptococcus agalactiae scrotype lb (ti098 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit

Philippinen - Englisch - FDA (Food And Drug Administration)

virbac philippines inc.; distributor: virbac philippines inc. - inactivated streptococcus agalactiae ser. ia, ib, iii fish vaccine (vet.) - emulsion for injection (ip) - each 0.1 ml (dose) contains: streptococcus agalactiae serotype ib (t1098 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype ia (ti191 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype iii (ti198 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection

Europäische Union - Englisch - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologicals for equidae - horses - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - potassium clavulanate, quantity: 7.4 mg/ml (equivalent: clavulanic acid, qty 6.25 mg/ml); amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; hypromellose; aspartame; succinic acid; xanthan gum; colloidal anhydrous silica; flavour - augmentin is indicated in the treatment of the following infections when caused by augmentin sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing s. aureus, e. coli and klebsiella spp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis & klebsiella spp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h.influenzae and m.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and s. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h.influenzae and m.catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin should not require the addition of another antibiotic due to the amoxicillin content of augmentin.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

nutrition care pharmaceuticals pty ltd - lactobacillus casei, quantity: 7.5 billion organisms; lactobacillus acidophilus, quantity: 7.5 billion organisms; lactobacillus salivarius ssp salivarius, quantity: 3 billion organisms; bifidobacterium longum, quantity: 4.5 billion organisms; lactobacillus plantarum, quantity: 7.5 billion organisms; lactobacillus rhamnosus, quantity: 9 billion organisms; bifidobacterium lactis, quantity: 4.5 billion organisms; streptococcus thermophilus, quantity: 1.5 billion organisms - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; ascorbic acid; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - maintain/support general health and wellbeing ; maintain/support intestinal health ; maintain/support intestinal good/beneficial/friendly flora ; maintain/support small intestine good/beneficial/friendly flora ; maintain/support gastrointestinal system health ; maintain/support gastrointestinal mucosal membrane health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support healthy gastrointestinal immune function